Drug manufacturer Lilly’s announcement last week that it is slashing the price of Humalog, its most commonly prescribed insulin, may have been less about altruism and more about avoiding exposure to bigger Medicaid rebates, a prominent drug pricing expert says.
…Category: Pharma Industry
Generic drug manufacturer Zydus Pharmaceuticals USA said in a recent public notice it will pay refunds for 340B overcharges that occurred mostly in the first two quarters of 2022. The products include Zydus’ equivalents of the widely prescribed antibiotic Zithromax,
…Associations representing community health centers and brand drug manufacturers are jointly developing 340B policy proposals for Congress to consider, hospital group 340B Health told its members yesterday.
The National Association of Community Health Centers said yesterday that it had no
…Johnson & Johnson, the world’s biggest drug company, yesterday announced a major expansion of the drug industry’s campaign to set limits on 340B drug sales.
On March 7, it is poised to become the first drug maker to place a
…Pharmaceutical manufacturer GlaxoSmithKline said last week it would pay refunds for 340B overcharges occurring in the first quarter of 2021, including overcharges for blockbuster respiratory drugs Trelegy and Nucala.
The refund notice posted Feb. 2 on the U.S. Health
…While the 340B program “has merit when used as intended,” it has “strayed far from its original purpose, creating a profit stream that is enriching middlemen versus benefitting patients,” drug manufacturer Bayer told 340B Report yesterday.
Bayer gave the statement
…Breaking News
EMD Serono Is the Second Drug Maker Today to Impose Conditions on 340B Contract Pharmacy, and the 21st Overall
EMD Serono today became the 21st pharmaceutical manufacturer to impose conditions on 340B pricing involving drug shipments to contract pharmacies.
Bayer announced conditions on 340B sales involving contract pharmacies earlier today. The companies’ announcements came two days after
…Bayer Healthcare Pharmaceuticals starting March 1 is imposing limits on hospitals’ replenishment orders of 340B-priced drugs shipped to contract pharmacies. It said it is voluntarily letting 340B grantee covered entities continue to use multiple contract pharmacies to dispense 340B drugs.
…Drug manufacturer Astellas will let 340B covered entities using “a compliant 340B inventory replenishment model” count accumulations of its antifungal Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, the company
…The 340B program “is buckling under its own weight and overdue for reform,” biotechnology industry trade group BIO said last week in its blog.
BIO, which is marking its 30th anniversary in 2023, has experienced inner turmoil in recent
…